Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

Data are presented on pharmacodynamic (PD) method validation and preliminary clinical qualification of three PD biomarker assays. M65 Elisa, which quantitates different forms of circulating cytokeratin 18 (CK18) as putative surrogate markers of both apoptotic and nonapoptotic tumour cell death, was...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Cummings, J, Ranson, M, LaCasse, E, Ganganagari, J R, St-Jean, M, Jayson, G, Durkin, J, Dive, C
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2006
Aiheet:
Translational Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360484/
https://ncbi.nlm.nih.gov/pubmed/16804528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603220
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia